Quantification of plasma lipids and apolipoproteins in British Halflop rabbits. A comparison between normocholesterolemic rabbits, hypercholesterolemic rabbits (modified WHHL rabbits) and rabbits fed an atherogenic diet.
We have established isolation methods and developed electroimmunoassays for rabbit apolipoprotein A-I (apo A-I), apo B, apo C-III and apo E. The assays were used to characterize a hyperlipidemic strain of the British Halflop rabbits (BHL rabbits), obtained after cross-breeding with WHHL rabbits and referred to as modified WHHL rabbits, and to investigate the changes in the apolipoprotein levels induced by feeding normal BHL rabbits an atherogenic diet (0.25% cholesterol and 3% coconut oil). The modified WHHL rabbits were characterized by increased levels of apo B, apo C-III and apo E as well as cholesterol, phospholipids and triacylglycerol as compared to chow-fed BHL rabbits, while the apo A-I levels were only half of those found in the chow-fed animals. The modified WHHL rabbits had virtually no low density lipoprotein (LDL) receptor activity and a low fractional catabolic rate (FCR) of LDL. These results indicate that the modified WHHL rabbit has the homozygous form of the LDL receptor deficiency. The BHL rabbits fed the atherogenic diet showed increased levels of cholesterol, triacylglycerol, apo B, apo C-III and apo E, as compared to those of the chow-fed BHL rabbits. The apo E and apo C-III reached levels in the range of or even higher than those of the modified WHHL rabbits. The apo A-I levels on the other hand did not differ from those of the chow-fed rabbits. Feeding an atherogenic diet led to a decrease in the FCR of LDL to a level similar to that found in the modified WHHL rabbits.
D000818:Animals; D016632:Apolipoprotein A-I; D053305:Apolipoprotein C-III; D001053:Apolipoproteins / Q000097:blood / Q000302:isolation & purification*; D001054:Apolipoproteins A / Q000302:isolation & purification; D001055:Apolipoproteins B / Q000097:blood / Q000302:isolation & purification; D001056:Apolipoproteins C / Q000097:blood / Q000302:isolation & purification; D001057:Apolipoproteins E / Q000097:blood / Q000302:isolation & purification; D002784:Cholesterol / Q000008:administration & dosage; D000074263:Coconut Oil; D003059:Cocos; D004036:Diet, Atherogenic / Q000009:adverse effects; D004041:Dietary Fats / Q000008:administration & dosage; D006937:Hypercholesterolemia / Q000097:blood*; D007122:Immunoelectrophoresis / Q000379:methods; D008297:Male; D010938:Plant Oils; D011817:Rabbits
D016632:Apolipoprotein A-I; D053305:Apolipoprotein C-III; D001053:Apolipoproteins; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D004041:Dietary Fats; D010938:Plant Oils; D002784:Cholesterol; D000074263:Coconut Oil